Project Details
Description
The EU Horizon 2020 funded SILICOFCM project (www.silicofcm.eu) will develop a computational platform for in silico clinical trials for familial cardiomyopathies capable of optimizing and testing medical treatment strategies to improve patients outcomes. As a Chief Investigator of a clinical workpackage, Professor Jakovljevic leads an international multicentre phase II clinical trial "Sacubitril/valsartan vs lifestyle in hypertrophic cardiomyopathy" (https://clinicaltrials.gov/ct2/show/NCT03832660).
Total project value €5,559,201.
Total project value €5,559,201.
| Short title | Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy |
|---|---|
| Acronym | SILICOFCM |
| Status | Finished |
| Effective start/end date | 1/06/18 → 28/02/22 |
Collaborative partners
- Coventry University
- Newcastle University (Project partner)
- University of Kent (Project partner)
- University Hospital Regensburg (Project partner)
- University of Kragujevac (Project partner)
- Careggi University Hospital (Project partner)
- University of Belgrade (Project partner)
- Washington State University (Project partner)
- Illinois Institute of Technology (Project partner)
- Seven Bridges Genomics (Project partner)
- Barcelona Supercomputing Center (Project partner)
- University of Ioannina (Project partner)
- University of Ljubljana (Project partner)
- BIOIRC - Bioengineering Research and Development Center (lead)
- University of Novi Sad (Project partner)
- Steinbeis Advanced Risk Technologies Gmbh R-Tech (Project partner)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.